B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma
Cancer research, 2003•AACR
In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune
evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of
the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on
immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express
B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive
T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T …
evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of
the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on
immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express
B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive
T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T …
Abstract
In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.
AACR